Diabetes Treatment: Expert Debate on Latest Advances

The ongoing quest to refine diabetes management took center stage at the recent Advanced Technologies and Treatments for Diabetes (ATTD) meeting, with a particularly lively debate focusing on whether A1c levels or continuous glucose monitoring (CGM) metrics should be considered the “gold standard” for assessing glycemic control. This isn’t simply an academic argument. the choice impacts how clinicians and patients track progress, adjust treatment, and manage a complex and often challenging condition.

The Shifting Landscape of Diabetes Monitoring

For decades, the hemoglobin A1c (A1c) test has been the primary yardstick for evaluating long-term blood sugar control. A1c reflects average blood glucose levels over the preceding two to three months, providing a snapshot of overall glycemic management. However, the rise of CGM technology – devices that track glucose levels in real-time through a sensor inserted under the skin – has introduced a wealth of new data, prompting questions about whether this more granular, dynamic information should take precedence.

The debate, as reported by Medscape Medical News, highlights a growing recognition that A1c, while valuable, has limitations. It provides an average, masking daily fluctuations and failing to capture the impact of individual meals, exercise, or stress on blood sugar levels. CGM data, offers a detailed picture of glucose variability, time spent in range (the percentage of time glucose levels are within a target range), and patterns of hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar).

What Do the Metrics Actually Measure?

Understanding the difference between A1c and CGM metrics requires a bit of unpacking. A1c is expressed as a percentage, with a higher percentage indicating poorer long-term control. The American Diabetes Association generally recommends an A1c target of below 7% for most adults with diabetes, though individualized goals are crucial. However, achieving a specific A1c target doesn’t necessarily guarantee a consistent, stable glucose profile.

CGM data, conversely, provides a continuous stream of glucose readings, allowing for the calculation of several key metrics. “Time in range” is increasingly recognized as a critical indicator of glycemic control, with a target of 70% or more of the day spent within a target range (typically 70-180 mg/dL) being a common goal. Other important metrics include glucose variability, which reflects the degree of fluctuation, and the frequency and duration of hyperglycemic and hypoglycemic episodes. These metrics offer a more nuanced understanding of glucose control than A1c alone.

The Debate at ATTD 2026: Two Perspectives

The discussion at the ATTD meeting, held in Barcelona from March 11-14, 2026 (ATTD 2026 – Medscape), featured two experts presenting differing viewpoints. While the specifics of their arguments weren’t detailed in the initial report, the core of the debate centers on whether the comprehensive data provided by CGM justifies a shift away from A1c as the primary metric for assessing diabetes control.

Proponents of CGM emphasize its ability to empower patients to make real-time adjustments to their diet, exercise, and medication, leading to improved glycemic outcomes and a reduced risk of complications. The ability to identify and address glucose excursions – sudden spikes or dips in blood sugar – can be particularly beneficial. However, critics point to the cost and accessibility of CGM technology, as well as the potential for “data overload” and alert fatigue, which can lead to decreased adherence.

Who Stands to Benefit from a Shift?

The implications of this debate extend beyond individual patients. A move towards prioritizing CGM metrics could influence clinical guidelines, insurance coverage decisions, and the development of new diabetes technologies. Individuals with type 1 diabetes, who require insulin therapy and are more prone to glucose fluctuations, may benefit most from the detailed insights provided by CGM. Similarly, people with type 2 diabetes who are struggling to achieve A1c targets despite conventional treatment may find CGM helpful in identifying and addressing specific challenges.

However, it’s important to note that CGM is not a one-size-fits-all solution. The technology requires a degree of technical proficiency and a willingness to actively engage with the data. For some individuals, particularly those who are older or have limited digital literacy, A1c may remain the more practical and accessible metric.

The Role of Incretin-Based Therapies

The discussion around A1c and CGM also intersects with advancements in diabetes medications, particularly incretin-based therapies like GLP-1 receptor agonists. These medications, which have gained prominence in recent years, have been shown to improve glycemic control, promote weight loss, and reduce cardiovascular risk. Medscape reported on GLP-1s being eyed as key to managing type 1 diabetes with obesity in April 2025. The effectiveness of these therapies may influence how clinicians interpret A1c and CGM data, and how they set treatment goals.

research presented at ATTD in March 2025, as highlighted by Medscape Education, focused on the evolution of incretin-based therapies in holistic diabetes management. This suggests a growing emphasis on personalized treatment approaches that consider the individual patient’s needs and preferences.

Limitations and Ongoing Research

It’s crucial to acknowledge the limitations of current research. The debate at ATTD represents an ongoing discussion, and more studies are needed to definitively determine the optimal approach to diabetes monitoring. Many studies evaluating CGM interventions are relatively short-term, and the long-term benefits and costs remain uncertain. The accuracy and reliability of CGM sensors can vary, and factors such as sensor placement and individual physiology can influence readings.

What Comes Next: A Gradual Evolution

The shift from A1c to CGM as the gold standard is unlikely to be abrupt. Instead, it’s likely to be a gradual evolution, driven by technological advancements, clinical research, and changing patient preferences. Expect to see continued refinement of CGM technology, with improvements in accuracy, ease of use, and affordability. Ongoing research will focus on identifying the optimal CGM metrics for different patient populations and developing algorithms to personalize treatment recommendations based on CGM data.

Clinicians will likely adopt a more integrated approach, using both A1c and CGM data to gain a comprehensive understanding of their patients’ glycemic control. A1c will likely remain a valuable tool for assessing long-term trends, while CGM will be used to provide real-time insights and guide day-to-day management. The goal is to empower individuals with diabetes to live healthier, more fulfilling lives.